At the American Diabetes Association (ADA) 2026 Scientific Sessions, Boehringer Ingelheim executives said survodutide’s tolerability is consistent with the class while responding to new Phase 3 details. Coverage of the Synchronize-1 study highlighted deep-dives into efficacy on an efficacy estimand and questions around side effects, including discontinuation rates and safety signal monitoring. Reported figures emphasized average weight loss versus placebo, plus analyses aimed at characterizing the “quality” of weight loss such as reductions in visceral fat and lean mass change. Boehringer also argued that weight loss is primarily driven by fat mass, referencing imaging sub-study outcomes. Investor and clinician focus remains on discontinuations and the safety profile of dual agonists as the market expands beyond injectable GLP-1s into broader multi-agonist obesity programs.